Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Heart Disease
Sort By
Newest First
1 / 1
1 / 1
Drug Approval
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer
PR-M05-19-NI-036
May 13, 2019
Drug Development
Novartis Licenses First-in-Class Heart Disease Drug
Emilie Branch
Pharma's Almanac
PAO-M03-19-NI-008
Mar 05, 2019
